Alphabiome.ai
Alphabiome.ai uses AI to read microbiome DNA and produce biomarkers that predict how patients will respond to treatments. The company applies proprietary, reference-free large-scale analysis of microbial DNA combined with machine learning to convert unaligned genetic fragments into predictive biomarkers. It operates as a B2B platform licensing IP-ready biomarkers and analytics to drug developers, diagnostics companies, and clinical researchers. The technology has been validated in large-scale animal studies and shown human proof-of-concept, supporting applications in drug development, clinical decision-making, and precision medicine.
Alphabiome.ai
Alphabiome.ai uses AI to read microbiome DNA and produce biomarkers that predict how patients will respond to treatments. The company applies proprietary, reference-free large-scale analysis of microbial DNA combined with machine learning to convert unaligned genetic fragments into predictive biomarkers. It operates as a B2B platform licensing IP-ready biomarkers and analytics to drug developers, diagnostics companies, and clinical researchers. The technology has been validated in large-scale animal studies and shown human proof-of-concept, supporting applications in drug development, clinical decision-making, and precision medicine.